Paul J Grippo

Feinberg School of Medicine, Feinberg Clinical, Surgery, Surgical Oncology Division

Paul J Grippo

Research Interest Keywords

Biotechnology, Cancer Biology, Cancer Genetics, Cancer: Pancreas, Immune System, Molecular Biology, Oncology, Transgenics

Office phone

Unavailable

Email

Scopus Publication Detail

The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.



Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer

Kevin Adrian; Matthew J. Strouch; Qinghua Zeng; Morgan R. Barron; Eric C. Cheon; Akilesh Honasoge; Yanfei Xu; Sharbani Phukan; Maureen Sadim; et al. (Profiled Authors: David Jason Bentrem; Paul J Grippo)

Cancer Research. 2009;69(24):9169-9174.

Abstract

To dissect the role of constitutively altered Tgfbr1 signaling in pancreatic cancer development, we crossed Elastase-KrasG12D (EL-Kras) mice with Tgfbr1 haploinsufficient mice to generate EL-Kras/Tgfbr1 +/- mice. Mice were euthanized at 6 to 9 months to compare the incidence, frequency, and size of precancerous lesions in the pancreas. Only 50% of all EL-Kras/Tgfbr1+/- mice developed preinvasive lesions compared with 100% of EL-Kras (wild-type Tgfbr1) mice. The frequency of precancerous lesions was 4-fold lower in haploinsufficient than in control mice. Paradoxically, the precancerous lesions of EL-Kras/Tgfbr1+/- mice were considerably larger than those in EL-Kras mice. Yet, the mitotic index of precancerous cells and the observable levels of fibrosis, lipoatrophy, and lymphocytic infiltration were reduced in EL-Kras/Tgfbr1+/- mice. We conclude that Tgfbr1 signaling promotes the development of precancerous lesions in mice. These findings suggest that individuals with constitutively decreased TGFBR1 expression may have a decreased risk of pancreatic cancer. ©2009 American Association for Cancer Research.


PMID: 19951995    

Scientific Context

This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.

Related Publications

Related Experts

Author of this Document